Prevent complications · MICA
Plan screening and consider prophylaxis according to treatment.
Sources consulted 16 October 2026 · MICA scientific review to be confirmed
Check for active infection and relevant exposures. Latent tuberculosis screening is recommended before biological or targeted synthetic therapy; IGRA is preferred to tuberculin testing when available. Follow local guidance. [1][2]
Establish hepatitis B status beforehand. Before rituximab, include at least HBsAg and anti-HBc; positive serology requires specialist input. Consider Pneumocystis prevention according to steroids, combined therapy and patient factors, without a universal threshold. [1][3]
Negative screening does not remove the need to reassess fever or a new exposure. [1]
Personal reading prompts; no clinical data is recorded.
FICTIONAL LEARNING SCENARIO
Positive anti-HBc, negative HBsAg before rituximab: can this result be ignored?
No. Past infection can reactivate: arrange specialist assessment and a prevention strategy. [3]
Non-exhaustive adult learning guidance. Check indication, contraindications, product information and local context before an individual decision. Cited recommendations do not establish marketing authorisation in Algeria.